Noticias de PFE_US
Noticias del mercado
Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Pfizer Inc. (NYSE:PFE) on Thursday presented detailed Phase 2 results for tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. The ongoing trial met its primary endpoint, showing a statistically significant increase in participants achieving EASI-75 at Week 16 across all evaluated doses compared to placebo. Strong Efficacy Across Phase 2 Trial Stages The trial evaluated biologic-naïve adult patients across two distinct stages. Stage 1 tested subcutaneous tilrekimig at 45
УНН Health ✎ Florida's attorney general accused Pfizer of misleading the public about the vaccine's safety and effectiveness. The state is seeking fines and the di…
Florida AG demanda a Pfizer, alegando marketing engañoso sobre la seguridad de la vacuna COVID-19 y riesgos ocultos. Lea más aquí.
Pfizer reported Phase 2 tilrekimig results showing improved EASI-75 responses in adults with moderate-to-severe atopic dermatitis.
Pfizer (PFE) says that more patients with atopic dermatitis who received its eczema drug tilrekimig had stronger skin clearance in a mid-stage trial. Read more here.
Pfizer Inc. reported a 61% EASI-75 response on monthly tilrekimig versus 9.1% on placebo at Week 16 in a Phase 2 atopic dermatitis study.
Pfizer (PFE) closed the most recent trading day at $28.1, moving 1.47% from the previous trading session.
Pfizer stock was at EUR 25.31 in after-hours trading at 9:41 p.m. CEST on September 30, 2026. It was
Pfizer stock reports higher 2026 guidance at EUR 25.28
Las tasas de EASI-75 estuvieron entre 38,7 y 51,9 puntos porcentuales por encima del placebo en las dosis de la Etapa 2; Pfizer ha comenzado la fase 3 de ensayos sobre eczema y asma.
Pfizer stock is at EUR 25.35 pre-market, up 0.20 percent versus the prior Lang & Schwarz close. Pfiz
Las acciones de Pfizer cotizaban a 25,25 euros fuera de horario a las 8:53 p.m. CEST el 29 de septiembre de 2026, un descenso del 0,16 por ciento
Carlyle Wins Dispute Over AI Platform Linked to Pfizer Covid Vax
Página 21 de 34